Compare RJET & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJET | PHAR |
|---|---|---|
| Founded | 1982 | 1988 |
| Country | United States | Netherlands |
| Employees | 8400 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.0M | 885.7M |
| IPO Year | N/A | 2020 |
| Metric | RJET | PHAR |
|---|---|---|
| Price | $17.79 | $12.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 181.4K | 8.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $0.21 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.37 | $9.54 |
| 52 Week High | $26.70 | $21.34 |
| Indicator | RJET | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 46.04 |
| Support Level | $17.90 | $11.88 |
| Resistance Level | $20.65 | $13.61 |
| Average True Range (ATR) | 1.10 | 0.48 |
| MACD | -0.10 | 0.13 |
| Stochastic Oscillator | 35.47 | 73.69 |
Republic Airways Holdings Inc is a regional airline mainly in North America. The company provides scheduled passenger service through its mainline partnerships with American Airlines, Delta Air Lines, and United Airlines. Republic offers scheduled passenger service on several daily flights to various cities in the United States, Canada, Mexico, and the Caribbean. It exclusively operates the dual-class Embraer E170/175 family of aircraft, and provides its services under the American Eagle, Delta Connection, or United Express brands. The company is organized and operates as one operating and reportable segment: regional airline services.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.